Avastin bevacizumab regulatory update

The U.K.'s NICE issued a final appraisal determination (FAD) recommending against Avastin bevacizumab from Roche in combination with a taxane for first-line treatment of metastatic breast cancer. The FAD is in line with a July preliminary appraisal (see BioCentury, July 12). NICE said Avastin offers limited and uncertain benefit for breast cancer patients compared with existing treatments. European Medicines Agency's CHMP began reviewing the benefit-risk profile of Avastin in the indication in September. ...